NCT00277290

Study of XL999 in Patients With Previously Treated Ovarian Cancer

A Phase 2 Study of XL999 Administered Intravenously to Subjects With Recurrent Ovarian Cancer

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 24 (actual)
• Sponsor: Symphony Evolution, Inc. · Industry
• Sex: Female
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This clinical trial is being conducted at multiple sites to evaluate the activity, safety, and tolerability of XL999 when given weekly to patients with ovarian cancer that has previously been treated with platinum-based chemotherapy. XL999 is a small molecule inhibitor of multiple kinases including VEGFR, PDGFR, FGFR, FLT-3, and Src, which are involved in tumor cell growth, formation of new blood vessels (angiogenesis), and metastasis.

Conditions

• Ovarian Cancer

Interventions

Type	Name	Description
DRUG	XL999	Treatment was administered on an outpatient basis. XL999 was administered at 2.4 mg/kg as a 4 hour intravenous (IV) infusion. Subjects received a XL999 infusion once a week for 8 weeks of treatment unless drug-related toxicity required a dosing delay

Timeline

• Start date: 2006-01-01
• Primary completion: 2006-11-01
• Completion: 2006-11-01
• First posted: 2006-01-16
• Last updated: 2010-02-22

Locations

9 sites across 1 country: United States